| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLAMF9 |
| Uniprot No | Q96A28 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-289aa |
| 氨基酸序列 | MCAFPWLLLLLLLQEGSQRRLWRWCGSEEVVAVLQESISLPLEIPPDEEVENIIWSSHKSLATVVPGKEGHPATIMVTNPHYQGQVSFLDPSYSLHISNLSWEDSGLYQAQVNLRTSQISTMQQYNICVYRWLSEPQITVNFESSGEGACSMSLVCSVEKAGMDMTYSWLSRGDSTYTFHEGPVLSTSWRPGDSALSYTCRANNPISNVSSCPIPDGPFYADPNYASEKPSTAFCLLAKGLLIFLLLVILAMGLWVIRVQKRHKMPRMKKLMRNRMKLRKEAKPGSSPA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLAMF9重组蛋白的虚构参考文献示例(内容为模拟创作，仅供参考)：
1. **文献名称**: "Recombinant SLAMF9 Protein Expression and Its Role in Macrophage Activation"
**作者**: Chen L, et al.
**摘要**: 研究利用大肠杆菌系统成功表达并纯化重组SLAMF9蛋白，发现其通过激活NF-κB通路促进巨噬细胞炎症因子分泌，提示其在先天免疫中的潜在调控作用。
2. **文献名称**: "Structural Characterization of SLAMF9 and Its Interaction with T-cell Receptors"
**作者**: Gupta R, et al.
**摘要**: 通过X射线晶体学解析重组SLAMF9胞外域结构，揭示其与T细胞表面受体CD48的结合位点，为SLAM家族蛋白的免疫调控机制提供结构基础。
3. **文献名称**: "SLAMF9 Recombinant Protein Modulates Tumor Microenvironment in Colorectal Cancer"
**作者**: Wang Y, et al.
**摘要**: 使用重组SLAMF9蛋白体外实验表明，其通过抑制肿瘤相关成纤维细胞(CAFs)的PD-L1表达，增强CD8+ T细胞抗肿瘤活性，提示其作为癌症免疫治疗靶点的潜力。
4. **文献名称**: "SLAMF9 Regulates B Cell Differentiation via Recombinant Protein-Mediated Signaling"
**作者**: Müller S, et al.
**摘要**: 研究发现重组SLAMF9蛋白通过结合B细胞表面受体SAP130.调控B细胞分化为浆细胞的过程，为自身免疫疾病中B细胞异常活化提供了新机制。
(注：以上文献及内容为模拟生成，实际研究请参考真实数据库。)
**Background of SLAMF9 Recombinant Protein**
SLAMF9 (Signaling Lymphocyte Activation Molecule Family Member 9) is a cell surface protein belonging to the SLAM family of immune receptors, which regulate innate and adaptive immune responses. These receptors are primarily expressed on hematopoietic cells and modulate immune cell interactions through homotypic or heterotypic binding. SLAMF9. also known as CD2F-10 or SF2001. is structurally characterized by an extracellular immunoglobulin (Ig)-like domain, a transmembrane region, and a cytoplasmic tail containing potential signaling motifs.
While the functional role of SLAMF9 remains less characterized compared to other SLAM members (e.g., SLAMF1. SLAMF6), studies suggest its involvement in immune regulation. It is expressed on macrophages, dendritic cells, natural killer (NK) cells, and certain T-cell subsets, implying roles in pathogen recognition, cell adhesion, or cytokine signaling. SLAMF9 may interact with undiscovered ligands or other SLAM receptors to modulate immune activation or tolerance. Notably, its expression has been linked to diseases such as cancer and autoimmune disorders, where dysregulated immune responses are critical.
Recombinant SLAMF9 protein is engineered for in vitro studies to elucidate its biological functions. Produced via mammalian or bacterial expression systems, it retains the extracellular domain for ligand-binding studies. Researchers use it to investigate SLAMF9’s interactions, signaling pathways, and potential as a therapeutic target. Applications include immune cell activation assays, structural studies (e.g., crystallography), and antibody development.
Despite progress, SLAMF9’s precise mechanisms and therapeutic relevance remain under exploration. Its study contributes to understanding immune checkpoint regulation and may inform novel immunotherapies for cancer or inflammatory diseases.
×
